Today: 19 November 2025
Subscribe
Browse Category

Vaccines News 14 August 2025 - 30 October 2025

Moderna Stock Soars on Buyout Buzz – Can New Vaccines Fuel a Comeback?

Moderna Stock Soars on Buyout Buzz – Can New Vaccines Fuel a Comeback?

Market Performance & Buyout Rumors On Oct. 30, 2025 Moderna’s stock jumped sharply. Midday trading saw MRNA up ~11.7% to about $27.56 tradingview.com, reversing much of September–October’s slide. This followed a STAT News report (cited by Reuters) that Moderna has held buyout or partnership talks with at least one large drugmaker tradingview.com. Moderna’s shares had been languishing near all-time lows (after falling roughly 90% from pandemic highs) tradingview.com, so today’s news sparked a relief rally. Even so, with the recent gain the stock remains roughly 37% below its Jan. 2025 price tradingview.com. (By comparison, the Nasdaq and biotech indices were
30 October 2025
 ·  ·  ·  ·  · 
CSL’s Vaccine Shock: Stock Plunges to 7-Year Low Amid Shareholder Revolt

CSL’s Vaccine Shock: Stock Plunges to 7-Year Low Amid Shareholder Revolt

Vaccine Slump Triggers Profit Downgrade and 7-Year Share Low CSL – Australia’s fourth-largest public company – stunned the market by cutting its profit outlook and delaying a major spinoff due to a steep and unexpected decline in flu vaccinations in the United States. In an AGM update on Oct. 28, the biotech revealed that U.S. influenza immunization rates are dropping far more than anticipated, undermining its Seqirus vaccine division’s performance reuters.com. CEO Paul McKenzie told shareholders that flu shot uptake in the U.S. was collapsing – a 12% decline in vaccination rates is now expected for the overall population (and 14% for seniors) this season marketscreener.com reuters.com.
28 October 2025
 ·  ·  ·  ·  · 
Moderna’s Wild Ride: Vaccine Hopes Fuel Stock Pop Amid “One-Hit Wonder” Fears

Moderna’s Wild Ride: Vaccine Hopes Fuel Stock Pop Amid “One-Hit Wonder” Fears

Stock Rebounds on Moderna’s “Make-or-Break” Week Moderna’s stock is back in the spotlight after a turbulent week of news that sent the Nasdaq-listed shares swinging. On Wednesday, MRNA jumped over 5%, climbing to around $27.7 by market close marketbeat.com. The mini-rally came amid a flurry of developments – from upbeat trial data on a new cancer vaccine to analysts debating whether Moderna’s future is bright or bleak. Even after the pop, however, Moderna’s stock is a shadow of its former self: shares have cratered roughly 80% below last year’s levels marketbeat.com and are down one-third in 2025 alone. The once
16 October 2025
 ·  ·  ·  ·  · 
Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

In-Depth Report COVID-19 Vaccines and U.S. Public Health Upheaval Targeted Fall Boosters, But Access Tightened: U.S. health authorities approved new monovalent COVID-19 vaccines (by Pfizer–BioNTech, Moderna, and Novavax) updated for the 2025–26 season reuters.com. Unlike prior booster rollouts, the FDA restricted under-65 eligibility to those with risk factors, aligning with guidance from HHS Secretary Robert F. Kennedy Jr., a longtime vaccine skeptic reuters.com. The change marks a sharp departure from broad eligibility in previous years. Officials and experts voiced concern that narrowing access could sow confusion over insurance coverage and leave many younger adults unprotected reuters.com reuters.com. Notably, the FDA
28 August 2025
 ·  ·  ·  ·  ·  ·  ·  · 
Miracle Cure, Mega-Deals & Vaccine Drama: Global Biotech & Health Roundup (Aug 13–14, 2025)

Miracle Cure, Mega-Deals & Vaccine Drama: Global Biotech & Health Roundup (Aug 13–14, 2025)

Breakthroughs in Biotech & Pharma Big Deals & Industry Moves Regulatory & Health Policy Updates Public Health Developments Noteworthy Medical Research Healthcare Technology & Innovation Sources: Official press releases, government health agency updates, and reputable media coverage were used in this report (including Reuters, Fierce Biotech/Pharma, Bloomberg, FDA/CDC/DSHS releases, and peer-reviewed journals). All source links are provided inline above for reference.
14 August 2025
 ·  ·  ·  ·  ·  ·  · 
Go toTop